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Abstract
Development of endocrine resistance during tumor progression represents a major challenge in the management of
estrogen receptor alpha (ERa) positive breast tumors and is an area under intense investigation. Although the underlying
mechanisms are still poorly understood, many studies point towards the ‘cross-talk’ between ERa and MAPK signaling
pathways as a key oncogenic axis responsible for the development of estrogen-independent growth of breast cancer cells
that are initially ERa+ and hormone sensitive. In this study we employed a metastatic breast cancer xenograft model
harboring constitutive activation of Raf-1 oncogenic signaling to investigate the mechanistic linkage between aberrant
MAPK activity and development of endocrine resistance through abrogation of the ERa signaling axis. We demonstrate for
the first time the causal role of the Aurora-A mitotic kinase in the development of endocrine resistance through activation of
SMAD5 nuclear signaling and down-regulation of ERa expression in initially ERa+ breast cancer cells. This contribution is
highly significant for the treatment of endocrine refractory breast carcinomas, because it may lead to the development of
novel molecular therapies targeting the Aurora-A/SMAD5 oncogenic axis. We postulate such therapy to result in the
selective eradication of endocrine resistant ERalow/2 cancer cells from the bulk tumor with consequent benefits for breast
cancer patients.
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Introduction
Approximately, 70% of human breast carcinomas fall into
luminal subtypes, which are estrogen receptor alpha (ERa) positive
[1]. ERa expression correlates with expression of progesterone
receptor (PR), lower tumor grade, response to endocrine therapy,
lower grade of aneuploidy, less frequent overexpression of HER-2
oncogene, bone metastases and slower rate of tumor recurrence
[2]. Despite the clinical benefit of hormonal treatment in patients
with ERa+ breast cancer, resistance to first and second-line
endocrine therapy remains a major clinical problem [3,4]. The
introduction of pure estrogen antagonists such as fulvestrant, to
overcome the apparent disadvantage of tamoxifen with its partial
agonist properties, did not resolve the endocrine resistance
problem [5]. Second-line therapy with other endocrine agents
such as aromatase inhibitors produces some beneficial effect but
for the most part serves merely to delay onset of endocrine
resistance [6]. In pre-clinical and clinical studies, development of
endocrine resistance is associated with an aggressive behavior
characterized by high frequency of distant metastases and poses a
significant problem that affects negatively the disease-free and
overall survival of breast cancer patients [7]. Response to one form
of endocrine therapy after resistance to a previous therapy is a
historically recognized observation that is the key to management
of patients with metastatic disease [8]. Importantly, subsequent
responses to serial endocrine therapy tend to be shorter, indicating
a gradual shift from ‘‘dependence on ERa signaling to alternative escape
oncogenic pathways’’ [9]. Several mechanisms of endocrine resistance
have been proposed including: ERa mutations, altered expression
of ERa coregulators, ligand-independent activation of ERa by
growth factor receptor kinases and down-regulation/loss of ERa
expression [3]. Importantly, whereas ‘‘acquired resistance’’ is
predominantly the consequence of estrogen-independent activa-
tion of ERa in cancer cells still harboring an intact ERa signaling
axis, ‘‘intrinsic resistance’’ is mostly likely due to down-regulation/loss
of ERa expression leading to endocrine panresistance and tumor
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progression and represents a serious challenge for the treatment of
ERa+ breast cancer patients [3]. For this reason, understanding
the oncogenic pathways responsible for the development of
resistance to endocrine therapy given before or after primary
surgery is imperative to develop innovative therapeutic strategies
aimed to suppress or at least delay recurrence and progression of
initially ERa+ breast tumors.
The discovery that breast carcinomas contain a sub-population
of cells harboring stem-like properties (cancer initiating cells) has
generated excitement because these cancer initiating cells may
represent the source of therapeutic failures, tumor recurrence and
poor clinical outcome [10]. It has also been demonstrated that
cancer cells that undergo through epithelial to mesenchymal
transition (EMT) acquire a basal CD44+/CD24low/2 cancer stem-
like phenotype with increased capacity for self-renewal, invasion,
drug resistance, and tumor progression [11]. Moreover, breast
cancer initiating cells display down-regulation of ERa and clonal
expansion of these CD44+/CD24low/2/ERalow/2 cancer cells
may be responsible for tumor recurrence and development of
distant metastases of initially ERa+ breast carcinomas [12,13].
Aberrant activation of HER-2/MAPK and TGFb/SMAD onco-
genic signalings induces EMT and plays an important role in the
maintenance of breast cancer initiating cells [14–16]. However,
the underlying molecular mechanisms responsible for ERa down-
regulation by aberrant activation of HER-2/MAPK and TGFb/
SMAD pathways remain elusive and are the subject of ongoing
investigation.
The mitotic kinase Aurora-A plays a key role in breast cancer
progression through the development of centrosome amplification
and chromosomal instability (CIN) [17–19]. Aurora-A is over-
expressed in human breast tumors and is associated with an
invasive ERalow/- basal-like phenotype and poor-prognosis
[20,21]. Moreover, it has been demonstrated that estrogen is
causally linked via ERa to Aurora-A overexpression, centrosome
amplification, CIN, and aneuploidy leading to breast tumors in
susceptible mammary gland cells [22]. Nonetheless, the causal role
of aberrant Aurora-A kinase activity in the development of
endocrine resistance and breast cancer progression through
molecular mechanisms that are independent from its mitotic
function and CIN remains elusive. Herein we demonstrate a
significant and novel non-mitotic role of Aurora-A kinase in the
induction of tumor progression of ERa+ breast cancer xenografts
through activation of EMT and the genesis of CD44+/CD24low/2
cancer initiating cells [23]. Moreover, these studies revealed a non
canonical cross-talk between Aurora-A kinase and SMAD5
oncogenic signaling in promoting EMT and invasiveness. We
demonstrate for the first time the causal role of Aurora-A/SMAD5
oncogenic axis in the development of endocrine resistance through
down-regulation of ERa expression in initially ERa+ breast cancer
cells. This contribution is important for the treatment of endocrine
refractory breast carcinomas, because it may lead to the
development of novel molecular therapies targeting the Aurora-
A/SMAD5 oncogenic axis. We postulate such therapy to result in
selective eradication of endocrine resistant ERalow/2 cancer cells
from the bulk tumor thereby delaying tumor progression with
consequent benefits on the progression-free and overall survival of
breast cancer patients.
Results and Discussion
Because development of endocrine resistance and progression of
ERa+ breast tumors is frequently characterized by aberrant
activation of MAPK signaling [24], we employed ERa+ MCF-7
cells over-expressing a constitutive active Raf-1 oncoprotein
(vMCF-7DRaf-1) as previously described [23,25]. In our previous
studies we have showed that vMCF-7DRaf-1 cells display MAPK
hyper-phosphorylation compared to parental MCF-7 cells, dem-
onstrating a constitutive activation of Raf/MAPK oncogenic
signaling. Importantly, constitutive activation of Raf/MAPK
signaling conferred higher migratory properties of MCF-7 cells
in vitro, predictive of an invasive phenotype that was validated in
vivo through the development of distant metastases in tumor
xenograft models. To investigate the extent to which metastatic
lesions derived from vMCF-7DRaf-1 xenografts displayed ERa
down-regulation, we established murine MCF-7 and vMCF-7DRaf-1
xenografts. Tumor xenografts were surgically removed 12 weeks
after implantation without sacrificing the animals to monitor the
development of distant metastases as previously described [25]. As
expected, 8 weeks following surgical removal, only vMCF-7DRaf-1
xenografts developed frank distant metastases (lung and spleen).
Importantly, vMCF-7DRaf-1 metastatic lesions showed ERa down-
regulation resulting in ERa+/2 cell heterogeneity compared to
MCF-7 and vMCF-7DRaf-1 primary tumors (Figure 1A). These
findings indicate that ERalow/2 cancer cells display more invasive
properties over ERa+ cancer cells in vivo and their clonal expansion
may induce tumor progression. To investigate whether vMCF-
7DRaf-1 primary tumors carried a singular sub-population of cancer
cells harboring an ERalow/- phenotype that was mostly observed in
the metastatic lesions described above, we re-cultured cells from
primary vMCF-7DRaf-1 tumor xenografts (referred to as first
generation derived from xenografts, 1GX). Significantly, vMCF-
7DRaf-1 1GX cells showed down-regulation of ERa expression due
to loss of ERa in ,28% of bulk cancer cells (Figure 1B–C). These
findings demonstrate that cancer cells harboring an ERalow/2
phenotype were already present in vMCF-7DRaf-1 primary tumors
and their clonal expansion may promote the onset of distant
metastases during tumor progression. Next we investigated whether
down-regulation of ERa expression was causally linked to
development of endocrine resistance in vMCF-7DRaf-1 1GX cells.
Parental MCF-7 and variant cells were treated in vitro with 17-b
Estradiol alone or in combination with the anti-estrogen 4-OH-
tamoxifen and endocrine sensitivity was determined by analyzing
the percentage of cancer cells in the S phase of the cell cycle. vMCF-
7DRaf-1 1GX cells displayed the highest resistance to 4-OH
tamoxifen compared to parental MCF-7 and vMCF-7DRaf-1 cells
indicating that down-regulation of ERa induces ‘‘intrinsic resistance’’
to conventional endocrine therapy (Figure 1D). Since we have
previously shown that tumor progression of vMCF-7DRaf-1 1GX
xenografts is causally linked to aberrant Aurora-A kinase activity
[23], we tested Aurora-A expression in MCF-7 and variant cells. As
demonstrated before, Aurora-A was over-expressed in vMCF-
7DRaf-1 1GX cells compared to parental cells (Figure 2A). Next we
investigated the causal role of Aurora-A kinase activity in the
development of endocrine resistance by employing alisertib, a novel
Aurora-A kinase small molecule inhibitor currently being tested in
oncology clinical trials [26]. We have previously demonstrated that
treatment of breast cancer cells with 1 mM alisertib selectively
inhibits Aurora-A kinase activity [23]. Specifically, our study
showed that the transcriptome profile of breast cancer cells treated
with alisertib or shRNA targeting Aurora-A displayed ,90% gene
expression overlapping demonstrating the high specificity of 1 mM
alisertib for targeting Aurora-A kinase activity. vMCF-7Raf1 1GX
cells that displayed strong 4-OH tamoxifen resistance were treated
with fulvestrant (a selective ERa down-regulator that increases ERa
degradation and inhibits estrogen signaling) alone or in combination
with alisertib. Combination of fulvestrant with alisertib induced a
stronger effect on inhibition of cell proliferation measured by Real-
Time Cell Proliferation Assay (Figure 2B). Based on our previous
Aurora-A/SMAD5 Axis in Endocrine Resistance
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results viewing a novel cross-talk between Aurora-A kinase and
SMAD5 oncogenic signaling in the development of EMT and
breast cancer progression [23], we also analyzed SMAD5 nuclear
phosphorylation in vMCF-7Raf1 1GX cells treated with fulvestrant
and/or alisertib. Importantly, restoration of endocrine sensitivity
was mechanistically linked to suppression of SMAD5 nuclear
phosphorylation (Figure 2C), demonstrating the causal role of
Aurora-A/SMAD5 oncogenic axis in the development of endocrine
resistance in initially ERa+ and hormone sensitive breast cancer
cells. Significantly, these findings were also validated by performing
immunoblotting analysis of vMCF-7Raf1 1GX cells treated with
fulvestrant and/or alisertib showing a selective alisertib-induced
down-regulation of SMAD5 phosphorylation (Figure 2D). Next we
wanted to investigate the causal role of Aurora-A/SMAD5
oncogenic axis in the development of ‘‘intrinsic resistance’’ to
conventional endocrine therapy through down-regulation of ERa
expression in initially ERa+vMCF-7Raf1 cancer cells. We employed
a lenti-vector engineered to over-express Aurora-A kinase and we
analyzed Aurora-A phosphorylation/activation, ERa and
p,SMAD5 nuclear localization in vMCF-7Raf-1 and vMCF-
7Raf-1/Aurora-A cells (Figure 3A–B). Our studies showed that aberrant
Aurora-A kinase activity induced down-regulation of ERa nuclear
localization that was functionally linked to increased SMAD5
nuclear phosphorylation (Figure 3B–C). Importantly, treatment of
vMCF-7Raf-1/Aurora-A cells with alisertib inhibited Aurora-A phos-
phorylation, restored ERa nuclear expression and suppressed
SMAD5 nuclear phosphorylation (Figure 3B–C). Moreover, the
causal role of Aurora-A kinase in the down-regulation of ERa
nuclear expression through activation of SMAD5 was validated by
employing a dominant negative (DN) Aurora-A construct that
abrogated Aurora-A kinase activity (Figure 3B–C). Significantly,
over-expression of Aurora-A in parental MCF-7 cells resulted in a
similar phenotype, although vMCF-7Raf-1/Aurora-A cells displayed a
stronger phosphorylation of nuclear SMAD5 and down-regulation
of ERa expression, demonstrating a synergistic cross-talk between
MAPK pathway and aberrant Aurora-A kinase activity in the
abrogation of ERa signaling (Figure S1). Finally, to investigate the
role of SMAD5 as a down-stream target of Aurora-A-induced ERa
down-regulation, we engineered MCF-7 over-expressing SMAD5
(Figure 4A). Notably, over-expression of SMAD5 in MCF-7 cells
induced down-regulation of ERa nuclear localization demonstrat-
ing the causal role of SMAD5 nuclear signaling in the development
of breast cancer cells harboring an ERalow/2 phenotype (Figure 4B–
C). Taken together, these results indicate that the partial response of
endocrine resistant vMCF-7Raf11GX cancer cells to fulvestrant is
likely due to its effect on the ERa+ sub-population that still retains a
functional ERa signaling. Inhibition of Aurora-A kinase activity by
alisertib impairs SMAD5 nuclear activation and restores ERa
expression in the subpopulation of ERalow/2 cancer cells leading to
restoration of endocrine sensitivity. Furthermore, our findings are
supported by recent studies that have demonstrated that down-
regulation of ERa expression is responsible for endocrine thera-
peutic failure and tumor progression of initially ERa+ breast tumors
[27]. Although it has already been demonstrated that key
transcription factors involved in the development of EMT such as
Snail and Slug induce down-regulation of ERa expression in breast
cancer cells [28,29], our findings establish a previously unrecog-
nized oncogenic signaling involved in the abrogation of ERa
function through activation of the Aurora-A/SMAD5 oncogenic
axis. Moreover, vMCF-7DRaf-1 breast cancer xenografts represent
an innovative and useful pre-clinical model to investigate the
mechanisms leading to endocrine panresistance and tumor
progression based on the clonal expansion of ERalow/2 cancer
cells. Importantly, although these studies are based on the vMCF-
Figure 1. Endocrine Resistant Breast Cancer Cells. (A) Immumohistochemistry staining of low-grade tubular tumors for MCF-7 and high-grade
vMCF-7DRaf-1 Primary and Metastatic tumors. Breast cancer xenografts were stained with a polyclonal antibody targeting the ERa (Abcam, Cambridge,
Massachusetts, USA). (B) Immunofluorescence analysis showing down-regulation of ERa expression in vMCF-7DRaf-1 1GX cancer cells compared to
parental MCF-7 and vMCF-7DRaf-1 cells. (C) Graph showing the percentage of cancer cells harboring an ERalow/2 phenotype from three independent
experiments (+/2 s.d.; *p,0.0705 vs. MCF-7; **p,0.0001 vs. vMCF-7DRaf-1). (D) Graph showing the percentage of cancer cells in the S phase of the cell
cycle during starvation from 17-b estradiol and following treatment with 17-b estradiol (10210 M) alone or in combination with 4-OH-tamoxifen
(1027 M) for 48 hours from three independent experiments (+/2 s.d.; *p,0.0008 vs. MCF-7; **p,0.0009 vs. vMCF-7DRaf-1).
doi:10.1371/journal.pone.0096995.g001
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7DRaf-1 xenograft model derived from one single cell line, global
gene expression analysis have shown that vMCF-7Raf1 1GX cancer
cells developed a distinct transcriptome signature characterized by
activation of EMT and stemness signalings compared to parental
MCF-7 cells [23].
Based on these findings and our published data [23,25], we
propose a novel model of endocrine resistance in initially ERa+
and hormone sensitive breast cancer cells: aberrant activation of
MAPK signaling promotes phosphorylation and stabilization of
Aurora-A kinase that in turn induces down-regulation/loss of ERa
expression through activation of SMAD5 nuclear signaling leading
to endocrine resistance and tumor progression (Figure 5). Because
our previous studies have demonstrated the causal role of aberrant
Aurora-A kinase activity in the development of CD44+/CD24low/2
cancer initiating cells [23], we speculate that Aurora-A/SMAD5
oncogenic axis may induce ERa down-regulation by promoting the
clonal expansion of CD44+/CD24low/- cancer initiating cells that
display low levels of ERa. Moreover, because Aurora-A is down-
stream of MAPK, we believe that molecular targeting of Aurora-A
in endocrine resistant breast cancer cells will be more effective than
targeting MAPK pathway due to Aurora-A direct effects on the
clonal expansion of CD44+/CD24low/2/ERalow/2 cancer initiating
cells [23]. However, we don’t exclude that patients with endocrine
resistant breast tumors could benefit from the combination of
MAPK and Aurora-A small molecule inhibitors.
In conclusion, our studies are of important translational
relevance because they will lay the groundwork for innovative
clinical trials employing small molecule inhibitors of Aurora-A
kinase to suppress the Aurora-A/SMAD5 oncogenic axis, restore
ERa expression and sensitivity to endocrine therapy for a subset of
hormone refractory breast tumors with anticipated benefits on the
progression-free and overall survival of breast cancer patients.
Materials and Methods
Human Breast Cancer Cell Lines
The human breast cancer cell line MCF-7 was obtained from
ATCC (Manassas, VA, USA). The MCF-7 cells over-expressing
the Raf-1 oncoprotein were generated as previously described
[23,25]. All cell lines were maintained in EMEM medium
containing 5 mM glutamine, 1% penicillin/streptomycin, 20
microgram insulin/ml and 10% FBS at 37C in 5% CO2
atmosphere.
Figure 2. Molecular characterization of endocrine resistant breast cancer cells. (A) Immunoblot analysis showing Aurora-A (Cell Signaling
Technology, Boston, MA, USA) over-expression in vMCF-7DRaf-1 1GX cancer cells compared to parental MCF-7 and vMCF-7DRaf-1 cells. (B) In Vitro Real
Time Cell Proliferation Assay showing stronger activity of Fulvestrant (50 nM) in combination with alisertib (50 nM) in tamoxifen resistant vMCF-7DRaf-1
1GX cancer cells. Experiments were performed in triplicate. (C) Immunofluorescence analysis showing inhibition of nuclear SMAD5 (Cell Signaling
Technology, Boston, MA, USA) phosphorylation in breast cancer cells treated with alisertib. p,SMAD5was labeled in red and nuclei were labeled in blue
with DAPI. (D) Immunoblot analysis showing selective alisertib-induced down-regulation of SMAD5 phosphorylation.
doi:10.1371/journal.pone.0096995.g002
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Tumor Xenografts and Immunohistochemistry
Procedures established by the Institutional Animal Care and
Use Committee based on US NIH guidelines for the care and use
of laboratory animals were followed for all experiments. Four-
week-old non-ovariectomized female NCR/Nu/Nu nude mice
were anesthetized by exposure to 3% isoflurane and five mice per
each group were injected subcutaneously with 26106 MCF-7 or
vMCF-7DRaf-1 cancer cells suspended in 50 ml of 50% Matrigel
(BD Bioscience, Bedford, MA, USA). Tumor localization and
growth was monitored using the IVS imaging system from the
ventral view 10 min after luciferin injection. After 12 weeks, mice
were killed and xenograft tumors were processed for histology, and
immunohistochemistry analyses. Paraffin-embedded tumor tissues
were stained with ERa antibody (Abcam, Cambridge, Massachu-
setts, USA) as previously described [23]. To re-establish cultures
from 1GX explants, primary tumors tissues were excised from
killed animals, minced using sterile scissors, transferred to
complete culture medium and fibroblast-free tumor cell lines were
established by serial passages in culture. Animals were examined
everyday and body weight and primary tumor size were measured
at least 1–2 times per week. Consistent distress and potential pain
(.1 day) were alleviated by euthanasia. If some of the animals
were loosing greater than 10% of their body weight, if blood was
consistently observed in the urine or around the genitals of the
mice, the mice were appropriately euthanized. When typical signs
of distress including labored breathing and inactivity were
consistently observed for .1 day, the animals were appropriately
euthanized. When the primary tumor was .2 cm, the animals
were sacrificed. Animals were euthanized using Pentobarbital (IP
100 mg/kg) followed by cervical dislocation. The Mayo Clinic
Institutional Animal Care and Use Committee (IACUC) approved
this study.
Fluorescence Microscopy
Cells were fixed in absolute methanol at 220uC for 10 min,
blocked in 5% normal goat serum, 1% glycerol, 0.1% BSA, 0.1%
fish skin gelatin, 0.04% sodium azide and incubated with primary
antibodies. Primary antibodies against the proteins ERa (Santa
Cruz Biotechnology, Delaware Avenue Santa Cruz, CA, USA)
and P,SMAD5 (Cell Signaling Technology, Boston, MA, USA)
were followed by secondary antibodies conjugated with Alexa 488
or Alexa 568 (Molecular Probes, Eugene, OR, USA). Images were
digitally recorded at multiple focal planes using a Zeiss Axiovert
200 M fluorescence microscope and analyzed as maximum
projections. Results are derived from three independent experi-
ments. Nuclear staining counting was performed employing the
ImageJ Software, experiments were performed in triplicate.
Figure 3. Mechanistic Linkage Between Aurora-A Over-expression, SMAD5 Activation And ERa Down-Regulation In Initially ERa+
Breast Cancer Cells. (A) Immunoblot analysis showing p,Aurora-A in breast cancer cells. (B) Immunofluorescence analysis showing that Aurora-A-
induced ERa down-regulation is linked to p,SMAD5 nuclear activation. ERa (Abcam, Cambridge, Massachusetts, USA) was labeled in green,
p,SMAD5 (Cell Signaling Technology, Boston, MA, USA) was labeled in red and nuclei were labeled in blue with DAPI. (C) Graph showing the
percentage of cells expressing ERa and p,SMAD5 in breast cancer cells. Experiments were performed in triplicate (+/2 s.d.; *p,0.0083 vs. vMCF-
7DRaf-1/Aurora-A; **p,0.0048 vs. vMCF-7DRaf-1/Aurora-A; ***p,0.0083 vs. vMCF-7DRaf-1/Aurora-A; ****p,0.0021 vs. vMCF-7DRaf-1/Aurora-A).
doi:10.1371/journal.pone.0096995.g003
Aurora-A/SMAD5 Axis in Endocrine Resistance
PLOS ONE | www.plosone.org 5 May 2014 | Volume 9 | Issue 5 | e96995
Endocrine Resistance Studies
For endocrine resistance studies, breast cancer cells were
cultured in phenol-red free medium with 5% FBS for 48 hours.
Following starvation from 17-b estradiol, cells were treated with
17-b estradiol (10210 M) alone or in combination with 4-OH-
tamoxifen (1027 M) for 48 hours. Results are derived from three
independent experiments (+/2 s.d.). Cell cycle profile was
performed by FACS as earlier described [23]. For In Vitro real
time cell proliferation assay we employed the xCELLigence
technology (ACEA). Following 48 hours starvation from 17-b
estradiol, cells were treated with Fulvestrant (50 nM) and/or
Alisertib (50 nM). Results are derived from three independent
experiments.
Immunoblot and Lenti-Vector Expression Studies
Immunoblot and lenti-vector expression studies were performed
as previously described [23]. Antibodies employed for the
immunoblot analysis were the followings: Aurora-A and
P,SMAD5 (Cell Signaling Technology, Boston, MA, USA).
The Dominant Negative (DN) Aurora-A vector was kindly
provided by Dr. Lomberk (Mayo Clinic, Rochester, MN).
Supporting Information
Figure S1 Role Of Aurora-A Over-Expression In ERa
Down-Regulation. (A) Immunoblot analysis showing parental
and MCF-7 cells engineered to over-express Aurora-A. (B)
Immunofluorescence analysis showing that Aurora-A over-expres-
sion induces partial ERa down-regulation and SMAD5 nuclear
phosphorylation in ERa+MCF-7 cells. ERa (Abcam, Cambridge,
Massachusetts, USA) was labeled in green, p,SMAD5 (Cell
Figure 4. Role Of SMAD5 Over-Expression In ERa Down-Regulation. (A) Immunoblot analysis showing parental and MCF-7 cells engineered
to over-express SMAD5. (B) Immunofluorescence analysis showing that SMAD5 over-expression induces ERa down-regulation in ERa+MCF-7 cells.
ERa (Abcam, Cambridge, Massachusetts, USA) was labeled in green, p,SMAD5 (Cell Signaling Technology, Boston, MA, USA) was labeled in red and
nuclei were labeled in blue with DAPI. (C) Graph showing the percentage of cells expressing p,SMAD5 and ERa in vMCF-7SMAD5 and parental cells.
Experiments were performed in triplicate (+/2 s.d.; *p,0.0001 vs. MCF-7; **p,0.0001 vs. MCF-7).
doi:10.1371/journal.pone.0096995.g004
Figure 5. Model of endocrine resistance and breast cancer
progression. Aberrant activation of MAPK signaling stabilizes and
activates Aurora-A kinase that in turn induces down-regulation/loss of
ERa expression through phosphorylation and activation of SMAD5
nuclear signaling leading to endocrine resistance and tumor progres-
sion.
doi:10.1371/journal.pone.0096995.g005
Aurora-A/SMAD5 Axis in Endocrine Resistance
PLOS ONE | www.plosone.org 6 May 2014 | Volume 9 | Issue 5 | e96995
Signaling Technology, Boston, MA, USA) was labeled in red and
nuclei were labeled in blue with DAPI. (C) Graph showing the
percentage of cells expressing p,SMAD5 and ERa in vMCF-
7SMAD5 and parental cells. Experiments were performed in
triplicate (+/2 s.d.).
(TIF)
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